225 related articles for article (PubMed ID: 36335418)
1. Benralizumab in the management of rare primary eosinophilic lung diseases.
Griscti Soler D; Bennici A; Brunetto S; Gangemi S; Ricciardi L
Allergy Asthma Proc; 2022 Nov; 43(6):494-500. PubMed ID: 36335418
[No Abstract] [Full Text] [Related]
2. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
5. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
6. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
7. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
8. Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis.
Matsuno O; Minamoto S
Respir Med Case Rep; 2022; 40():101763. PubMed ID: 36353062
[TBL] [Abstract][Full Text] [Related]
9. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
10. Eosinophilia Induced by Blocking the IL-4/IL-13 Pathway: Potential Mechanisms and Clinical Outcomes.
Olaguibel JM; Sastre J; Rodríguez JM; Del Pozo V
J Investig Allergol Clin Immunol; 2022 Jun; 32(3):165-180. PubMed ID: 35522053
[TBL] [Abstract][Full Text] [Related]
11. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I; Angelopoulos A; Daoussis D
Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
[TBL] [Abstract][Full Text] [Related]
14. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
15. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
16. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Severe Eosinophilic Asthma Associated With ANCA-Negative EGPA in a Young Adult Successfully Treated With Benralizumab.
Ricciardi L; Soler DG; Bennici A; Brunetto S; Pioggia G; Gangemi S
Front Pharmacol; 2022; 13():858344. PubMed ID: 35462932
[No Abstract] [Full Text] [Related]
18. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
19. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis.
Tsurikisawa N; Oshikata C; Watanabe M; Tsuburai T; Kaneko T; Saito H
Clin Exp Allergy; 2018 Oct; 48(10):1305-1316. PubMed ID: 29908086
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
